Shortening the Diagnostic Journey With AI
Our data science community spans every therapeutic area, with particular focus on cancer, inflammatory conditions, rare blood disorders, rare diseases, vaccines, and neurological disorders.
At every level of R&D, we’re building scalable data platforms to shorten the diagnostic journey and improve both public health and the standard of care for diseases.
Data-Driven Discovery
AI helps us accelerate R&D for patients. To leverage data at all stages of drug discovery, we develop, extend, and apply AI methods including:
-
deep neural networks and other technologies for target identification
-
active learning for drug and molecule design
-
graphical models for integrating clinical and molecular data to improve clinical trials.
Real-World Evidence (Rwe)
We collaborate across disciplines to discover and validate digital biomarkers of disease. We use AI, bioinformatics, and other methods to find meaningful patterns in complex, multi-dimensional datasets.
For example, to anticipate flare-ups in patients with some conditions, we can use AI and data from smart devices, wearables, electronic health records, genomics, proteomics, and real-time environmental measures.
Open Science and Collaboration
Open science helps us do more. Through Open Targets, we work with academic and industry partners to improve drug-target identification and prioritization. And in partnership with small- and medium-sized enterprises, we identify new targets, mine RWE to gain new insights into disease drivers, and use large datasets to build disease models while preserving privacy.
Follow the Science
AI helps our teams discover digital biomarkers for disease, zero in on new targets, and even redefine diseases.
AI Goes Industrial
How Digital Technologies Are Accelerating Our Drug Discovery and Development Process
Partner Spotlight: Owkin and Sanofi Embrace the “Golden Era” of Precision Medicine With AI
Page updated September 2023